Therapeutic strategies within the ubiquitin proteasome system

Cell Death and Differentiation

Volumn 17, Issue 1, 2010, Pages 4-13

  Eldridge, A G ^a   O'Brien, T ^a  

^a GENENTECH INC   (United States)

Author keywords

DUB; E3 ligase; proteasome; small molecule inhibitor; ubiquitin

Indexed keywords

BENZODIAZEPINE; BORTEZOMIB; CARFILZOMIB; CULLIN; ENZYME INHIBITOR; LIGASE; NEDD8 PROTEIN; NEREUS; NSC 632839; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SERDEMETAN; TDP 665759; UBIQUITIN; UBIQUITIN LIGASE E1; UBIQUITIN LIGASE E2; UNCLASSIFIED DRUG; UBIQUITIN PROTEIN LIGASE;

DRUG STRUCTURE; DRUG TARGETING; EUKARYOTE; HUMAN; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; RING FINGER MOTIF; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NEOPLASM; PROTEIN DOMAIN; PROTEIN PROCESSING;

EUKARYOTA;

ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN PROCESSING, POST-TRANSLATIONAL; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 77449103325     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.82     Document Type: Review

References (88)

1. Reed SI. The ubiquitin-proteasome pathway in cell cycle control. Results Probl Cell Differ 2006; 42: 147-181. (Pubitemid 44856951)
2. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005; 7: 758-765.
3. Kostova Z, Tsai YC, Weissman AM. Ubiquitin ligases, critical mediators of endoplasmic reticulum-associated degradation. Semin Cell Dev Biol 2007; 18: 770-779. (Pubitemid 350138452)
4. Vembar SS, Brodsky JL. One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol 2008; 9: 944-957.
5. Huen MS, Chen J. The DNA damage response pathways: at the crossroad of protein modifications. Cell Res 2008; 18: 8-16.
6. Kodadek T, Sikder D, Nalley K. Keeping transcriptional activators under control. Cell 2006; 127: 261-264. (Pubitemid 44572383)
7. Wang J, Maldonado MA. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 2006; 3: 255-261.
8. Lin AE, Mak TW. The role of E3 ligases in autoimmunity and the regulation of autoreactive T cells. Curr Opin Immunol 2007; 19: 665-673. (Pubitemid 350236811)
9. Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006; 6: 776-788. (Pubitemid 44450466)
10. Layfield R, Lowe J, Bedford L. The ubiquitin-proteasome system and neurodegenerative disorders. Essays Biochem 2005; 41: 157-171. (Pubitemid 41500977)
11. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006; 443: 780-786. (Pubitemid 44622682)
12. Pearce MJ, Mintseris J, Ferreyra J, Gygi SP, Darwin KH. Ubiquitin-like protein involved in the proteasome pathway of mycobacterium tuberculosis. Science 2008; 322: 1104-1107.
13. Peng J, Schwartz D, Elias JE, Thoreen CC, Cheng D, Marsischky G et al. A proteomics approach to understanding protein ubiquitination. Nat Biotechnol 2003; 21: 921-926. (Pubitemid 36936199)
14. Tokunaga F, Sakata S-i, Saeki Y, Satomi Y, Kirisako T, Kamei K et al. Involvement of linear polyubiquitylation of NEMO in NF-[kappa]B activation. Nat Cell Biol 2009; 11: 123-132.
15. Sun L, Chen ZJ. The novel functions of ubiquitination in signaling. Curr Opin Cell Biol 2004; 16: 119-126. (Pubitemid 38757287)
16. Hicke L. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2001; 2: 195-201. (Pubitemid 33675744)
17. Nakamura M, Tokunaga F, Sakata S-I, Iwai K. Mutual regulation of conventional protein kinase C and a ubiquitin ligase complex. Biochem Biophys Res Commun 2006; 351: 340-347. (Pubitemid 44666695)
18. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005; 123: 773-786. (Pubitemid 41721026)
19. Song L, Rape M. Reverse the curse-the role of deubiquitination in cell cycle control. Curr Opin Cell Biol 2008; 20: 156-163.
20. Huang L, Kinnucan E, Wang G, Beaudenon S, Howley PM, Huibregtse JM et al. Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science 1999; 286: 1321-1326.
21. Verdecia MA, Joazeiro CA, Wells NJ, Ferrer JL, Bowman ME, Hunter T et al. Conformational flexibility underlies ubiquitin ligation mediated by the WWP1 HECT domain E3 ligase. Mol Cell 2003; 11: 249-259. (Pubitemid 36126605)
22. Ogunjimi AA, Briant DJ, Pece-Barbara N, Le Roy C, Di Guglielmo GM, Kavsak P et al. Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to the HECT domain. Mol Cell 2005; 19: 297-308. (Pubitemid 41074886)
23. Zheng N, Wang P, Jeffrey PD, Pavletich NP. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 2000; 102: 533-539.
24. Lovering R, Hanson IM, Borden KL, Martin S, O'Reilly NJ, Evan GI et al. Identification and preliminary characterization of a protein motif related to the zinc finger. Proc Natl Acad Sci USA 1993; 90: 2112-2116. (Pubitemid 23078575)
25. Freemont PS. The RING finger. A novel protein sequence motif related to the zinc finger. Ann NY Acad Sci 1993; 684: 174-192. (Pubitemid 23218950)
26. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005; 6: 9-20. (Pubitemid 40064895)
27. Chew E-H, Poobalasingam T, Hawkey CJ, Hagen T. Characterization of cullin-based E3 ubiquitin ligases in intact mammalian cells - evidence for cullin dimerization. Cell Signal 2007; 19: 1071-1080. (Pubitemid 46436442)
28. Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL. Structure of the MDM2//MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 2008; 15: 841-848. (Pubitemid 351524426)
29. Coscoy L, Ganem D. PHD domains and E3 ubiquitin ligases: viruses make the connection. Trends Cell Biol 2003; 13: 7-12. (Pubitemid 35453890)
30. Aravind L, Koonin EV. The U box is a modified RING finger - a common domain in ubiquitination. Curr Biol 2000; 10: R132-R134. (Pubitemid 30146770)
31. Ohi MD, Vander Kooi CW, Rosenberg JA, Chazin WJ, Gould KL. Structural insights into the U-box, a domain associated with multi-ubiquitination. Nat Struct Biol 2003; 10: 250-255. (Pubitemid 36418748)
32. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6: 909-923. (Pubitemid 44862676)
33. Lai Z, Yang T, Kim YB, Sielecki TM, Diamond MA, Strack P et al. Differentiation of Hdm2- mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci USA 2002; 99: 14734-14739. (Pubitemid 35334553)
34. Davydov IV, Woods D, Safiran YJ, Oberoi P, Fearnhead HO, Fang S et al. Assay for ubiquitin ligase activity: high-throughput screen for inhibitors of HDM2. J Biomol Screen 2004; 9: 695-703.
35. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7: 547-559. (Pubitemid 40799248)
36. Huang J, Sheung J, Dong G, Coquilla C, Daniel-Issakani S, Payan DG. High-throughput screening for inhibitors of the e3 ubiquitin ligase APC. Methods Enzymol 2005; 399: 740-754. (Pubitemid 41772765)
37. Xu S, Patel P, Abbasian M, Giegel D, Xie W, Mercurio F et al. In vitro SCFbeta-Trcp1- mediated IkappaBalpha ubiquitination assay for high-throughput screen. Methods Enzymol 2005; 399: 729-740. (Pubitemid 41772764)
38. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848. (Pubitemid 38174664)
39. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LGGC, Masucci M et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10: 1321-1328. (Pubitemid 40022713)
40. Koblish HK, Zhao S, Franks CF, Donatelli RR, Tominovich RM, LaFrance LV et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Therapeut 2006; 5: 160-169.
41. IDdb3 IDD P53 Strategies for Fighting Cancer - A visiongain Conference (Part I), Follow the Guardian Angel of the Genome From Cutting Edge Research to Large Scale Patient Care, London, UK 2008. Available from: http://www.iddb3.com/ iddb3/iddb3-2/reports.display?id968219&templateMeeting&i-query- id10342193.
42. Jin J, Li X, Gygi SP, Harper JW. Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature 2007; 447: 1135-1138. (Pubitemid 47014428)
43. Pelzer C, Kassner I, Matentzoglu K, Singh RK, Wollscheid HP, Scheffner M et al. UBE1L2, a novel E1 enzyme specific for ubiquitin. J Biol Chem 2007; 282: 23010-23014. (Pubitemid 47311897)
44. Chiu YH, Sun Q, Chen ZJ. E1-L2 activates both ubiquitin and FAT10. Mol Cell 2007; 27: 1014-1023. (Pubitemid 47488190)
45. Szczepanowski RH, Filipek R, Bochtler M. Crystal structure of a fragment of mouse ubiquitin-activating enzyme. J Biol Chem 2005; 280: 22006-22011. (Pubitemid 40827854)
46. Houben K, Dominguez C, van Schaik FM, Timmers HT, Bonvin AM, Boelens R. Solution structure of the ubiquitin-conjugating enzyme UbcH5B. J Mol Biol 2004; 344: 513-526. (Pubitemid 39441221)
47. Sekizawa R, Ikeno S, Nakamura H, Naganawa H, Matsui S, Iinuma H et al. Panepophenanthrin, from a mushroom strain, a novel inhibitor of the ubiquitin-activating enzyme. J Nat Prod 2002; 65: 1491-1493. (Pubitemid 35239640)
48. Tsukamoto S, Hirota H, Imachi M, Fujimuro M, Onuki H, Ohta T et al. Himeic acid A: a new ubiquitin-activating enzyme inhibitor isolated from a marine-derived fungus, Aspergillus sp. Bioorg Med Chem Lett 2005; 15: 191-194. (Pubitemid 39575810)
49. Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, Ludwig RL et al. Inhibitors of ubiquitinactivating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 2007; 67: 9472-9481. (Pubitemid 47535937)
50. Lin Y, Hwang WC, Basavappa R. Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10. J Biol Chem 2002; 277: 21913-21921. (Pubitemid 34952345)
51. Ozkan E, Yu H, Deisenhofer J. Mechanistic insight into the allosteric activation of a ubiquitin-conjugating enzyme by RING-type ubiquitin ligases. Proc Natl Acad Sci USA 2005; 102: 18890-18895. (Pubitemid 43049537)
52. Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res 2003; 63: 4167-4173. (Pubitemid 36917942)
53. Berlingieri MT, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G et al. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene 2006; 26: 2136-2140. (Pubitemid 46514746)
54. Rabut G, Peter M. Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008; 9: 969-976.
55. Huang DT, Ayrault O, Hunt HW, Taherbhoy AM, Duda DM, Scott DC et al. E2-RING Expansion of the NEDD8 Cascade Confers Specificity to Cullin Modification. Mol Cell 2009; 33: 483-495.
56. Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, Schulman BA. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 2008; 134: 995-1006.
57. Saha A, Deshaies RJ. Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. Mol Cell 2008; 32: 21-31.
58. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-736.
59. Fukuda I, Ito A, Hirai G, Nishimura S, Kawasaki H, Saitoh H et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem Biol 2009; 16: 133-140.
60. Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006; 66: 6379-6386.
61. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-1144. (Pubitemid 36323723)
62. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 14: 1649-1657. (Pubitemid 351469448)
63. Verma R, Peters NR, D'Onofrio M, Tochtrop GP, Sakamoto KM, Varadan R et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 2004; 306: 117-120. (Pubitemid 39451952)
64. Chen L, Madura K. Rad23 promotes the targeting of proteolytic substrates to the proteasome. Mol Cell Biol 2002; 22: 4902-4913. (Pubitemid 34620423)
65. Elsasser S, Chandler-Militello D, Muller B, Hanna J, Finley D. Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome. J Biol Chem 2004; 279: 26817-26822. (Pubitemid 38812515)
66. Verma R, Oania R, Graumann J, Deshaies RJ. Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system. Cell 2004; 118: 99-110. (Pubitemid 38902817)
67. Progenra Progenra scientists speak at the international symposium 'Drug targets in the Ubiquitin Proteasome System; tools for identifying potential drug targets in the UPS, 2008. Available from: http://www.progenra.com/company-news. html.
68. Aleo E, Henderson CJ, Fontanini A, Solazzo B, Brancolini C. Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. Cancer Res 2006; 66: 9235-9244. (Pubitemid 44521145)
69. Nicholson B, Leach CA, Goldenberg SJ, Francis DM, Kodrasov MP, Tian X et al. Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities. Protein Sci 2008; 17: 1035-1043. (Pubitemid 351749209)
70. Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA 2001; 98: 8554-8559. (Pubitemid 32678066)
71. Zhang D, Baek SH, Ho A, Kim K. Degradation of target protein in living cells by smallmolecule proteolysis inducer. Bioorg Med Chem Lett 2004; 14: 645-648. (Pubitemid 38114844)
72. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274: 948-953. (Pubitemid 26398409)
73. Chen C, Matesic LE. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev 2007; 26: 587-604. (Pubitemid 350119775)
74. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005; 121: 1071-1083. (Pubitemid 40884397)
75. Adhikary S, Marinoni F, Hock A, Hulleman E, Popov N, Beier R et al. The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell 2005; 123: 409-421. (Pubitemid 41546672)
76. Beaudenon S, Huibregtse JM. HPV E6, E6AP and cervical cancer. BMC Biochem 2008; 9 (Suppl 1): S4.
77. Centner T, Yano J, Kimura E, McElhinny AS, Pelin K, Witt CC et al. Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J Mol Biol 2001; 306: 717-726. (Pubitemid 33027694)
78. Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J et al. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene 2004; 23: 6621-6629. (Pubitemid 39265525)
79. Li M, Brooks CL, Kon N, Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 2004; 13: 879-886. (Pubitemid 38438482)
80. Cummins JM, Rago C, Kohli M, Kinzler KW, Lengauer C, Vogelstein B. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 2004; 428: 1 p following 486.
81. van der Horst A, de Vries-Smits AM, Brenkman AB, van Triest MH, van den Broek N, Colland F et al. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nat Cell Biol 2006; 8: 1064-1073. (Pubitemid 44473601)
82. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 2004; 5: 253-261. (Pubitemid 38402117)
83. Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S et al. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res 2006; 66: 8625-8632. (Pubitemid 44449177)
84. McCullough J, Clague MJ, Urbe S. AMSH is an endosome-associated ubiquitin isopeptidase. J Cell Biol 2004; 166: 487-492. (Pubitemid 39097168)
85. Li Z, Wang D, Messing EM, Wu G. VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. EMBO Rep 2005; 6: 373-378. (Pubitemid 40561631)
86. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 2007; 9: 765-774. (Pubitemid 47019463)
87. Jackson G, Einsele H, Moreau P, Miguel JS. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 2005; 31: 591-602. (Pubitemid 41662886)
88. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8: 407-419. (Pubitemid 41579835)